Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
06:00am, Wednesday, 21'st Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study
Alger Capital Appreciation Fund Q4 2025 Portfolio Update
12:58pm, Tuesday, 20'th Jan 2026
Class A shares of the Alger Capital Appreciation Fund underperformed the Russell 1000 Growth Index during the fourth quarter of 2025. Alphabet Inc., Western Digital Corporation, and Natera, Inc. were
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary
Campbell & CO Investment Adviser LLC Acquires Shares of 5,145 Natera, Inc. $NTRA
04:31am, Tuesday, 20'th Jan 2026
Campbell and CO Investment Adviser LLC bought a new stake in Natera, Inc. (NASDAQ: NTRA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchan
Alger Spectra Fund Q4 2025 Portfolio Update
10:20am, Monday, 19'th Jan 2026
Class A shares of the Alger Spectra Fund underperformed the Russell 3000 Growth Index during the fourth quarter of 2025. Alphabet Inc., Natera, Inc., and Cidara Therapeutics, Inc. were among the top c
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:46pm, Tuesday, 13'th Jan 2026
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
11:45am, Tuesday, 13'th Jan 2026
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
08:00am, Tuesday, 13'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
10:00am, Monday, 12'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the developme
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
10:48pm, Sunday, 11'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year
Farther Finance Advisors LLC Lowers Position in Natera, Inc. $NTRA
04:02am, Thursday, 08'th Jan 2026
Farther Finance Advisors LLC decreased its position in shares of Natera, Inc. (NASDAQ: NTRA) by 77.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange
Pre-Market Stock Futures: The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit another record high, closing over $49,000 for the
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
08:00am, Wednesday, 07'th Jan 2026
ALAMEDA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
07:25pm, Monday, 05'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
07:00am, Monday, 05'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera's expanded 21-gene Fetal Focus single gene no
